Month: February 2026

PRESS RELEASE Arcueil, February 23, 2026 Declaration of transactions on own shares conducted from February 16 to February 20, 2026 Within the framework of the authorizations granted by the General Assembly on February 3, 2026, to operate on its shares and in accordance with the regulations related to share buybacks, Aramis Group hereby declares the following purchases of own shares (FR0014003U94) made from February 16 to February 20, 2026 (excluding the liquidity contract):Name of the issuer Issuer identifier code Transaction date Financial instrument identifier code Total daily volume (in number of shares) Daily weighted average purchase price of shares MarketAramis Group 9695002Q984W0T41WB42 2026-02-16 FR0014003U94 4,850 4.1229 XPARAramis Group 9695002Q984W0T41WB42 2026-02-17 FR0014003U94 4,689 4.1760 XPARAramis Group 9695002Q984W0T41WB42 2026-02-18 FR0014003U94 4,769 4.1935 XPARAramis...

Embedding AI in Sonos workflows is creating a new benchmark for efficiency, operational intelligence and risk mitigation NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) — EXL [Nasdaq: EXLS], a global data and AI company, today announced a critical transformation initiative with Sonos (Nasdaq: SONO), the world’s leading sound experience company, and Amazon Web Services (AWS). This unique collaboration deploys agentic AI within Sonos IT service management (ITSM) workflows, aiming to create a new benchmark for efficiency, operational intelligence and risk mitigation. The initiative brings together Sonos innovative culture, EXL’s deep expertise in AI-led solutions and the powerful cloud infrastructure of AWS. The initiative represents a significant step forward in applying sophisticated AI to real-world enterprise scenarios. By harnessing...

LONDON and NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) — OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced that its abstract has been accepted for presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting, taking place May 3-7, 2026, in Denver, Colorado. Chief Scientific Officer Raj Patil, Ph.D., will share the data in a presentation titled: “First-in-Human Study of Urcosimod to Treat Neuropathic Corneal Pain (NCP) Shows Clinically Meaningful Pain Reduction and Quality-of-Life Improvement in NCP Patients.” This presentation highlights positive results from OKYO’s recently completed proof-of-concept Phase 2a...

ATHENS, Greece, Feb. 23, 2026 (GLOBE NEWSWIRE) —  Rubico Inc. (Nasdaq: RUBI) (the “Company” or “Rubico”), a global provider of shipping transportation services specializing in the ownership of vessels, announced today that it has entered into an agreement with Central Mare Inc, an affiliate of Mr. Evangelos Pistiolis, (“the Seller”), to acquire 100% of the issued and outstanding shares of a Marshall Islands company (the “SPV”), counterparty to a ship building contract for a very-high specification 47,499 dwt Medium Range (“MR”) product/chemical oil tanker with Guangzhou Shipyard International Company Limited, scheduled for delivery during 2029. The ship building contract effectiveness is subject to the issuance of a customary refund guarantee and the acquisition of the SPV is subject to conclusion of financing arrangements. Specifically,...

Appointments add decades of defense, security, and international program experience to T3 Defense’s executive team NEW YORK and TEL AVIV, Israel, Feb. 23, 2026 (GLOBE NEWSWIRE) — T3 Defense Inc. (NASDAQ: DFNS),  a strategic acquirer and developer of high-potential businesses in the Aerospace and Defense (A&D) sector, formerly Nukkleus Inc., today announced two senior leadership appointments aimed at strengthening execution, scalability, and long-term production reliability. T3 Defense appointed Emil Blumer as Chief Business Officer and Jordan Buchler as Chief Executive Officer of its Manufacturing & Industrial Processing Division, aligning commercial growth and operational execution around the industrial capabilities that most directly influence production continuity. As Chief Business Officer, Mr. Blumer is responsible...

DENVER, Feb. 23, 2026 (GLOBE NEWSWIRE) — Wall Street opens to a convergence of science, scale, and strategic consolidation. From spider silk making mainstream headlines to multibillion-dollar oncology deals and accelerating immunotherapy revenues, today’s tape reflects capital flowing toward platforms with validation. Kraig Biocraft Laboratories Featured on National Geographic Cover Shares of Kraig Biocraft Laboratories (OTCQB:KBLB) could see elevated interest after the company’s recombinant spider silk technology landed on the cover of the March 2026 issue of National Geographic.The feature, The Quest for Spider Silk, spotlighted Kraig’s genetically enhanced silkworm platform, engineered to spin recombinant spider silk as part of the animal’s natural biological process. The coverage included facility tours and demonstrations...

Enables millions of VIZIO customers free 24/7 access to music, podcasts, and live events directly from their smart TVsExpands LiveOne’s B2B distribution to over 1.3+ billion monthly active users (MAUs) including Apple, Spotify, ART19, YouTube, Paramount, Telly, Telsa, DAX, TextNow and othersExpects at least two additional Fortune 250 B2B partnerships by year-endLOS ANGELES, Feb. 23, 2026 (GLOBE NEWSWIRE) — LiveOne (Nasdaq: LVO), a creator-first music, entertainment, and technology platform, today announced the addition of its award-winning app on VIZIO and on smart TVs with VIZIO OS. Now, VIZIO customers have easy round-the-clock access to LiveOne’s music service on their connected devices, for free, via the LiveOne app. LiveOne is a comprehensive entertainment hub for music, podcasts, and live video content, with features...

Webinar on February 27 at 9:30 AM ET will have key opinion leaders discuss recent and upcoming clinical development of XPro1595 Boca Raton, FL, Feb. 23, 2026 (GLOBE NEWSWIRE) — INmune Bio Inc. (NASDAQ: INMB) (“INmune” or the “Company”), a late-stage biotechnology company focused on inflammation and immunology, will host a webinar focused on the registrational pathway of XPro1595 (“XPro™”) for the treatment of early Alzheimer’s disease on February 27, 2026 at 9:30 a.m. ET. Post the completion of the Phase 2 MINDFuL trial, along with feedback from the FDA in a recent End-Of-Phase 2 meeting, the Company has received alignment supporting advancement to a registrational study in patients with Alzheimer’s Disease with biomarkers of Inflammation. Webinar Focus: From Phase 2 Results to Phase 3 Readiness XPro™ is a next-generation,...